According to a recent study, extending the dosing interval of guselkumab from eight weeks to sixteen weeks is non-inferior for treating moderate-to-severe psoriasis in super-responders.
top of page
it's where dermatology lives
bottom of page
According to a recent study, extending the dosing interval of guselkumab from eight weeks to sixteen weeks is non-inferior for treating moderate-to-severe psoriasis in super-responders.
Commentaires